TY  - JOUR
T1  - TReatment of sepsis-related organ dysfunction
AU  - Rodríguez-Baño J
Y1  - 2012/09/26
N1  - 10.1001/2012.jama.11262
JO  - JAMA
SP  - 1205
EP  - 1206
VL  - 308
IS  - 12
N2  - 
To the Editor: In the study by Dr Brunkhorst and colleagues,1 the effect of empirical treatment with moxifloxacin and meropenem on sepsis-related organ dysfunction in patients with severe sepsis was compared with meropenem alone. Randomized clinical trials usually compare a new treatment or concept with the standard of care. In this trial, none of the groups were provided the standard of care. The authors stated that they excluded patients with “ . . . infections for which the guidelines recommend an antimicrobial therapy other than the study medication (ie, endocarditis). . . . ” However, 50.3% of included patients had a community-acquired infection. Meropenem should not be considered the standard of care for most community-acquired infections, even if presenting with severe sepsis because the majority of patients can be treated with narrower-spectrum agents.

SN  - 0098-7484
M3  - doi: 10.1001/2012.jama.11262
UR  - http://dx.doi.org/10.1001/2012.jama.11262
ER  -